What to watch for in the new biotech quarter
New year, new quarter. So STAT’s Adam Feuerstein has again compiled a rundown of biotech developments expected to move stocks in the first quarter.
Top of mind, of course, is Biogen. The company told investors that it will file a submission to the FDA for its Alzheimer’s drug aducanumab in early 2020, which sure sounds like the first quarter. There's plenty of action to be on the lookout for beyond that, though: A February inter partes review for Mylan, Phase 3 NASH drug results from France’s Genfit, an FDA decision on Aimmune’s peanut allergy drug Palforzia, and lots more.
Top of mind, of course, is Biogen. The company told investors that it will file a submission to the FDA for its Alzheimer’s drug aducanumab in early 2020, which sure sounds like the first quarter. There's plenty of action to be on the lookout for beyond that, though: A February inter partes review for Mylan, Phase 3 NASH drug results from France’s Genfit, an FDA decision on Aimmune’s peanut allergy drug Palforzia, and lots more.
.png)
No hay comentarios:
Publicar un comentario